Media Contact

    • 19 December 2018
    • Geilfuss, Faget Comment on Implications of Possible ACA Ruling

    • Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional.
    • 15 August 2018
    • Foley Attorneys Recognized In The Best Lawyers in America 2019 List

    • Foley announced today that 27 of its attorneys earned Best Lawyers 2019 “Lawyer of the Year” recognition in their respective practice areas. In addition, 242 of the firm’s attorneys in 19 offices have been listed in The Best Lawyers in America 2019.
    • 25 July 2018
    • Rosen Comments on FDA Plan to Facilitate Biosimilars

    • Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
    • 15 May 2018
    • Rosen Comments on Proposed Changes in FDA Drug-Device Rules

    • Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
    • 26 April 2018
    • Koski Comments on Prospects for Prescription Drug Legislation

    • Partner Katy Koski was quoted in a Pharmaceutical Technology article, “CREATES Act Dropped But May Still See Progress,” about the chances that legislation aimed at lowering the costs of prescription drugs will be taken up by Congress this year.
    • 29 December 2017
    • Beaver Addresses FDA’s Planned New Guidance for Drug Developers

    • Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development.
    • 15 December 2017
    • Brinckerhoff Discusses Recent Federal Circuit Decision on Biosimilar with Bloomberg Law

    • Partner Courtenay Brinckerhoff was quoted in a Bloomberg Law Patent, Trademark & Copyright Journal – Daily Edition article, “Biosimilars Statute Trumps State Law, Appeals Court Rules,” about a recent U.S. Court of Appeals for the Federal Circuit ruling on the Biologics Price Competition and Innovation Act.
    Filters applied:
    Search phrase entered: